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Context: Androgen deprivation therapy (ADT) is a common prostate cancer (PCa) treatment but
results in muscular atrophy. Periodic increases in muscle protein synthesis (MPS) that occur after
resistance exercise or protein intake may ameliorate this muscle loss, but the impact of these
anabolic stimuli during ADT is unclear.
Objective: To determine the acute MPS response to whey protein supplementation with and
without resistance exercise during ADT.
Design: Acute response in PCa patients vs age-matched controls (CON).
Setting: Academic laboratory setting.
Participants: PCa patients on ADT (N = 8) and CON (N = 10).
Intervention: A standardized diet was consumed for 2 days prior to performing unilateral knee
extension resistance exercise followed by ingestion of 40 g of whey protein.
Main Outcome Measures: Bilateral biopsies and stable isotope infusions were used to determine
MPS rates at rest after protein ingestion with and without resistance exercise.
Results: Baseline MPS during ADT was suppressed relative to CON (P = 0.01). Protein consumption
stimulatedMPS in both groups (approximate twofold increase, both P, 0.001), but to a greater extent
inCON (P=0.003). Proteinplus resistanceexercise increasedMPS (;3.4-fold increase, bothP,0.001) toa
greater extent than did protein alone (P , 0.001), but with no difference between groups (P = 0.380).
Conclusions: ADT reduces basal and protein feeding-induced rises in MPS; however, combined protein
ingestion with resistance exercise stimulated MPS to a similar degree as CON. Testosterone appears to
play a role in maintaining muscle mass but is not necessary to initiate a robust response in MPS following
resistanceexercisewhencombinedwithprotein ingestion. (JClinEndocrinolMetab102: 1076–1083, 2017)
Prostate cancer (PCa) is the most common non-dermatological form of cancer in US men and is
the second leading cause of cancer-related death (1).
Androgen deprivation therapy (ADT) is a common ad-
juvant treatment that slows tumor growth but is asso-
ciated with adverse effects, notably significant declines in
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Abbreviations: ADT, androgen deprivation therapy; CON, controls; Ex-Fed, 40 g of whey
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whey protein ingestion; MPB, muscle protein breakdown; MPS, muscle protein synthesis;
PCa, prostate cancer; SD, standard deviation.
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muscle mass, strength (2–4), and physical function (4, 5),
which negatively impact health-related quality of life. The
iatrogenic effects of ADT on musculoskeletal health are
similar to sarcopenia, but they present at an accelerated
rate (6, 7). Because age-related and ADT-induced re-
ductions in health-related quality of life are treatable,
therapies to offset these side effects are crucial to PCa
patients undergoing hormone therapy.
During the past decade, exercise interventions have
been used to reduce the side effects of PCa treatment.
Resistance training during ADT improves muscle func-
tion, reduces fatigue, and enhances physical function and
quality of life (7–14). Thus, repeated bouts of resistance
exercise are beneficial during ADT and address some of
the treatment-related side effects. However, whether
significant muscle hypertrophy occurs with ADT fol-
lowing resistance training remains controversial. Some
studies report no change inmusclemass (10, 13), whereas
others showed increased mass compared with non-
exercise controls (9, 11). Our most recent work (8)
demonstrated muscle hypertrophy similar to healthy
older adults (15), suggesting that the muscle’s capacity to
respond to a sufficient loading stimulus remains intact
despite ADT.
Although the role of ADT on load-mediated hyper-
trophy is unclear, pharmacological manipulation of
testosterone impacts skeletal muscle mass (16). Muscle
protein synthesis (MPS) significantly increased in older
men when testosterone was restored to that of youngmen
(17), suggesting that testosterone ablation impairs resting
MPS. Indeed, 10 weeks of ADT decreased whole-body
protein synthesis, strength, and lean mass in young men
(18). However, MPS has yet to be examined specifically
in PCa patients, who may respond differently than young
men due to differences in age, length of ADT, or other
cancer-related treatments. To minimize muscle loss
during ADT, it is necessary to shift the balance between
MPS and muscle protein breakdown (MPB) to favor an
anabolic environment. Resistance exercise and protein
supplementation stimulate MPS, effects that are syner-
gistic when used concurrently (19). Of the available
protein supplements, whey protein produces the greatest
increases in acute MPS (20) and augments lean muscle
mass accretion with resistance training (21). Higher
protein doses are needed tomaximizeMPS in older adults
(22–24) whereas less is required in younger individuals
(25, 26). Thus, this age-related “anabolic resistance” to
feeding warrants consideration for interventions in
clinical populations, including patients receiving ADT.
There are relatively few resistance training studies
performed during ADT (14). None has examined the
effects of resistance exercise or protein supplementation
on MPS during PCa treatment, yet both appear to be
attractive options to reduce muscle loss during ADT.
Given the importance of muscle mass and strength on
physical function and quality of life, strategies to mini-
mize ADT-related detriments to musculoskeletal health
must be further explored. Moreover, determining the
acute response provides important information for de-
signing future resistance exercise and dietary in-
terventions to maximize the MPS and subsequent
hypertrophic response. Therefore, the purpose of this
study was to determine the acute MPS response to whey
protein supplementation with (Ex-Fed) and without
(Fed) resistance exercise in PCa patients on ADT rel-
ative to healthy age-matched men. It was hypothesized
that baseline MPS would be suppressed with ADT but
that diet- and resistance-induced increases in MPS
would be independent of ADT.
Methods
Participants
Eight men (age 68 years [standard deviation (SD), 5 years])
with physician-diagnosed PCa on ADT for at least 3 months
[559 days (331 days)] were recruited for this trial. Ten healthy
men [age 70 years (4 years)] with no history of PCa that
had previously completed an identical trial served as controls
(CON), as published previously (23). Healthy age-matched
CON were selected, as they represent the best case MPS re-
sponse to Fed or Ex-Fed and provide context on the magnitude
of the MPS changes from rest.
All participants were generally healthy andwere not engaged
in regular resistance training; their physical characteristics are
described in Table 1. Most participants were low to moderately
active. CON were all nonsmokers and had no history of di-
abetes. Men on ADT were currently nonsmokers, although
several previously smoked, and one participant had controlled
diabetes (managed via diet only). Men on ADT had approval
from their physician to participate in the study. Participants
were informed of the study procedures and the potential risks
and all gave their written informed consent. The project was
approved by the local ethics committees at the PeterMacCallum
Cancer Centre, Victoria University, and McMaster University
and was conducted in accordance with principles set out in the
Declaration of Helsinki.
Design
Both groups of oldermen (ADT andCON) consumed 40 g of
whey protein isolate immediately following a single session of
unilateral knee extension exercises. Previously, 40 g of protein
produced the highest MPS rates (23) and exceeded the 0.4 g/kg
needed to observe a plateau in MPS in older adults (24). The
unilateral model permits each participant to serve as his own
resting control with muscle biopsies being obtained immedi-
ately and 240 minutes after resistance exercise (see “Muscle
biopsies”).
Preliminary assessments
Preliminary assessments for CONwere described previously
(23) and were followed exactly for the ADT group. Briefly, two
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weeks before the trial day, body composition was determined
using dual-energy x-ray absorptiometry (Hologic, Waltham,
MA). Participants performed a 5-minute cycling warm-up and
were familiarized with the knee extension exercise before
maximal unilateral strength was determined. Two submaximal
warm-up sets were completed before a series of single repetitions
with increasing resistance were performed until participants
were unable to complete the full range of motion. Oneminute of
rest separated each attempt. One week later, testing was re-
peated and the highest value was used to determine maximal
strength. Physical function was assessed using the short physical
performance battery, as described by Guralnik et al. (27), im-
mediately prior to strength testing.
Dietary control
Three-day dietary food records were used to estimate normal
macronutrient intake. Participants were instructed to record all
food and drink, as described previously (23). Average daily
caloric requirements and total protein intake were estimated
using the Harris–Benedict equation and adjusted based on
participant-reported activity levels after meeting with the study
dietician. Standardized diets containing 1.0 g/kg/day of protein
for the 2 days prior to the trial were administered to the par-
ticipants by the study dietician. Participants were otherwise
instructed to keep dietary and physical activity habits consistent
throughout their study participation.
Trial protocol
Between 7:00 and 7:30 AM, participants reported to the
laboratory in the fasted state. Bilateral intravenous catheters
were inserted for (1) stable isotope infusion and (2) repeat blood
sampling with a 0.9% saline drip to keep the catheter patent.
Priming doses of L-[ring-13C6]-phenylalanine (2 mmol/kg; 99
atom percent; Cambridge Isotopes, Tewksbury, MA) were
delivered followed by continuous infusion (0.05 mmol/kg/
minute) throughout the trial. Arterialized blood samples were
obtained at regular intervals by warming the arm using a
custom-built heater for 10 minutes prior to sampling or using a
heat blanket, as described previously (23). After 2.5 hours of
infusion, participants completed three sets of unilateral knee
extensions using a predetermined load (70% of maximal
strength) thatwas set at their 10-repetitionmaximum, separated
by 2 minutes of rest. Participants were verbally encouraged to
complete as many repetitions as possible until fatigue ensued.
This resistance exercise protocol has demonstrated large in-
creases in MPS (23, 28). Immediately following exercise, par-
ticipants consumed 40 g of whey protein isolate (General
Nutrition Company, Pittsburgh, PA) dissolved in 400 mL of
water. The protein beverage was enriched to 8% L-[ring-13C6]-
phenylalanine to minimize disturbances to the isotopic steady-
state, as validated previously (29).
Muscle biopsies
Muscle samples were obtained from the vastus lateralis
using a 5-mm Bergstrom needle (modified for manual suction),
under 2% local anesthesia. Bilateral biopsies were obtained
immediately and 240 minutes after protein consumption. All
samples were blotted dry and any visible fat or connective tissue
was removed prior to freezing in liquid nitrogen.
Muscle analyses
Myofibrillar-enriched protein fractions and intracellular
amino acidswere isolated from separate;30mg and;20mgof
wet muscle, respectively, as described previously (23, 28).
Blood analyses
L-[ring-13C6]-phenylalanine enrichments from plasma were
determined as described previously (23). Blood amino acid
concentrations were analyzed by HPLC as previously de-
scribed (23). Total testosterone (Immulite 2000; Siemens
Immulite, Erlangen, Germany) and prostate-specific antigen
levels (Sigma-Aldrich, Oakville, ON, Canada) were measured
at the McMaster University Core Laboratory Facility. Within-
assay coefficient of variation was less than 5% and between
assay variability ,7%. The minimum detectable concentra-
tion of total testosterone was 5 ng$dL21 and prostate specific
antigen was 0.1 mg/mL.
Protein synthesis calculations
MPS for myofibrillar proteins was calculated using the
standard precursor-product method: MPS (%/hour) = (Ep2 2
Ep1)/Eic3 1/t3 100, where Ep2 and Ep1 are the protein-bound
enrichments from biopsies obtained at 240minutes and baseline
plasma proteins, respectively. The difference represents the
change in bound protein enrichment between time points. Eic
is the mean intracellular phenylalanine enrichment from
biopsies taken from both legs at t = 240 minutes, and t is the
exact tracer incorporation time in hours. Tracer-naive par-
ticipants allowed for the use of preinfusion blood samples
(i.e., a mixed plasma protein fraction) as a surrogate baseline
enrichment of muscle protein, as previously described (23,
28, 30) and validated (29).
Statistical analyses
Differences between groups were analyzed using a mixed
model analysis of variance. Following the observation of a
significant F ratio by analysis of variance, Bonferroni-adjusted
Table 1. Participant Characteristics
CON
(N = 10)
ADT
(N = 8)
P
Value
Age, y 70 (4) 68 (5) 0.372
Body mass index,
kg/m2
26.0 (2.2) 30.0 (3.5) 0.029
Height, m 1.75 (0.09) 1.71 (0.08) 0.309
Mass, kg 80.7 (12) 87.8 (9.7) 0.204
Lean mass, kg 56.0 (9) 58.0 (7.8) 0.685
% Fat 27.0 (8) 29.5 (5.1) 0.843
SPPB 11.6 (0.7) 11.6 (0.7) 0.942
KE 1RM, kg 56.5 (12.5) 49.0 (12.2) 0.221
Total testosterone,
ng/dL
430.2 (146.0) 45.7 (4.9) ,0.001
PSA, ng/mL 2.8 (0.7) 2.6 (0.6) 0.732
Time since
diagnosis, d
— 1498 (1546) —
Length of ADT, d — 559 (331) —
Tumor stage — 2 (1) —
Gleeson score — 8 (1) —
Data are expressed as mean (SD).
Abbreviations: KE 1MR, knee extensionmaximal strength; PSA, prostate-
specific antigen; SPPB, short physical performance battery.
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t tests were used for post hoc analyses. Localization of
significant interaction was determined using simple main
effect analyses. Correlations were used to examine the re-
lationship between ADT length and resting MPS. Statistical
significance was set at P , 0.05. All statistical analyses were
performed using SPSS 20 for MacIntosh. Data are reported as
mean (SD).
Results
No group differences existed for age, height, body mass,
functional status, or knee extension strength; men onADT
had a significantly greater body mass index (P = 0.029,
Table 1). Men on ADT had suppressed total testosterone,
which was below the clinical definition of low testosterone
(,50 ng/dL), with levels significantly less than those of
CON (P , 0.001). The average duration of ADT was
18 months.
Plasma 13C6-phenylalanine enrichment remained con-
stant following protein intake and resistance exercise and
throughout the trial [Fig. 1(A)]. The tracer added to the
protein drink resulted in an unaltered tracer-to-tracee
ratio, indicating that isotopic equilibrium was present
throughout the infusion. Plasma [Fig. 1(A)] and intra-
cellular phenylalanine [Fig. 1(B)] enrichment levels with
ADT were similar to CON, with no differences between
Fed and Ex-Fed or between groups.
Blood leucine concentration increased 4.2-fold after
protein consumption in ADT patients at 90 minutes
[P , 0.001, Fig. 2(A)] and remained elevated above
baseline (2180minutes) throughout the trial (P, 0.05).
A similar pattern was observed for branched chain
amino acid concentration, with a 3.2-fold increase over
baseline (P , 0.001) at 90 minutes that also remained
elevated throughout the trial [P , 0.05, Fig. 2(B)].
For MPS, there was a significant group 3 time in-
teraction [P , 0.001, Fig. 3(A)]. Compared with CON
[0.0250 (0.004%/hour)], men on ADT had a 0.7-fold
decrease in MPS at rest (P = 0.001) and a 0.5-fold de-
crease at 240 minutes in Fed (P , 0.001), but the group
difference in Ex-Fed did not reach significance (P = 0.054).
At 240 minutes, MPS was 1.7-fold higher for ADT and
2.3-fold higher for CON compared with baseline in Fed
(both P , 0.001), but there was a greater change in
CON [DADT, 0.0118 (0.0062%/hour); DCON, 0.0314
(0.0148%/hour); P = 0.003]. In Ex-Fed, MPS for ADT
and CON was 3.5- and 3.3-fold higher than baseline
and 2.1- and 1.5-fold higher than Fed, respectively (all
P , 0.001), but the absolute change from baseline was
not different between groups [DADT, 0.0451 (0.0083%/
hour);DCON, 0.0584 (0.0271%/hour); P = 0.380]. ADT
length did not appear to influence resting MPS rates
[r = 0.152, P = 0.720, Fig. 3(B)].
Figure 1. (A) 13C6-phenylalanine enrichment measured and shown at tracer (tr)-to-tracee (t) ratio in the in plasma was stable, as shown from 30
to 240 minutes after exercise. (B) 13C6-phenylalanine intracellular (IC) pool enrichment as determined from the 240 minute biopsy samples from
the nonexercised (Fed) and exercised (Ex-Fed) legs. Data are expressed as mean (SD).
Figure 2. Blood amino acid profiles in men on ADT across the trial for (A) leucine and (B) total branched chain amino acids (BCAA). Time points
with different letters were significantly different (P , 0.05) from each other. All data are presented as mean (SD).
doi: 10.1210/jc.2016-3383 press.endocrine.org/journal/jcem 1079
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Discussion
The primary findings from this study were that men with
PCa on ADT had reduced basal and protein feeding–
induced rises in MPS, indicating a role for testosterone in
maintaining these rates. However, when protein in-
gestion followed resistance exercise, increases in MPS in
men on ADT exceeded those seen in protein alone and
were of a similar magnitude and were not statistically
significantly different from the optimal response seen in
healthy elderly men. This suggests that ADT reduces
resting MPS and in response to a protein-containing
meal; however, men receiving ADT are still able to
initiate a robust response in MPS following resistance
exercise and consumption of an effective dose (0.4 to
0.5 g/kg) of whey protein (23, 24). This supports our
previous work showing significant muscle hypertrophy
is possible following high-intensity resistance training in
men with PCa on ADT (8).
Testosterone’s role in muscle hypertrophy is complex.
Evidence from older adults strongly indicates that tes-
tosterone administration increases MPS and lean mass
accretion (16, 17). Moreover, androgen suppression re-
duced resting MPS by 39%, as shown in this study, and
whole-body protein synthesis by 12.5% (18). This de-
crease in MPS likely contributes to the 1% to 2% re-
duction in lean mass seen during the first 6 to 12 months
of ADT (2–4). Muscle atrophy that accompanies ADT is
insidious, persisting even after 24 to 36 months of
treatment with little muscle mass change in non-ADT
PCa patients or controls (2, 3). Resistance training is an
attractive lifestyle choice to mitigate muscle loss, given its
success in other clinical populations, but data are am-
biguouswhenADT and resistance training are combined.
Early studies in PCa patients onADT indicated no change
in body composition and little evidence of muscle hy-
pertrophy following resistance training (10, 31). This was
supported by a recent year-long study combining mod-
erate intensity resistance training and impact training
(13). Other studies have shown modest (0.5 to 0.7 kg)
muscle hypertrophy with resistance training during ADT
(9, 11) compared with nonexercising controls, but that
training responses may be compromised by ADT (32).
Finally, our group has demonstrated a 1.8 kg increase in
lean mass following high-intensity resistance training (8)
that exceeded all other studies using PCa patients on
ADT, and we have shown that the gains in knee extensor
strength (28% vs 28%), knee extensor power (15% vs
16%), and total body lean mass (2.7% vs 1.9%) were
similar to healthy men of similar age performing an
identical training routine (15). Interestingly, only PCa
patients showed a tendency to improve lean mass
whereas all other types of cancer survivors demonstrated
little change in a recent systematic review of resistance
training following treatment (12). Collectively, these data
suggest that muscle hypertrophy is possible during
treatment of PCa; however, differences in study meth-
odologies may preclude a clear effect.
Exercise oncology is an emerging field and initial
studies used relatively conservative exercise interventions
because the risk of potential adverse events was unknown
(10, 31). We hypothesize that the heterogeneous hyper-
trophic responses previously reported after resistance
training in PCa patients are most likely due to reduced
training intensities or volumes used during ADT that
were insufficient to stimulate MPS and lean mass ac-
cretion. We propose that this thesis is more likely as
opposed to an inherent muscle-related deficit due to
testosterone deficiency. In support of this thesis, we re-
port in this study that men on ADT demonstrated robust
increases in MPS and that the absolute change from
baseline was similar to CON in Ex-Fed. Although ad-
mittedly not hypertrophy, MPS increases are indicative
that the capacity of the muscle to respond to a loading
stimulus is intact. In the present study, resistance exercises
were performed to volitional fatigue, and this may be a
critical element driving the increased MPS, regardless of
Figure 3. (A) Myofibrillar MPS (%/hr) at rest and 240 minutes after consumption of 40 g of protein (Fed) or 40 g of protein combined with
resistance exercise (Ex-Fed) in CON vs ADT. (B) The association between length of ADT and resting MPS during PCa treatment. Data are
presented as mean (SD). *Significantly different from CON at the specific time point (P , 0.01); †significantly different from baseline value
(P , 0.001; ‡Significantly different from baseline and Fed condition (P , 0.001).
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concentrations of testosterone, training volume, or in-
tensity. For example, three sets of knee extension to
failure induced a 3.1-fold increase in MPS whereas a
single set elevated MPS 2.1-fold in healthy individuals
(28). The absolute load may also not be critical, as light
(30% of maximum) and heavy (90% of maximum) re-
sistance exercise to fatigue increases myofibrillar MPS to
the same degree (33). In our previous work, men on ADT
performed 15 repetitions, beginning at a load equivalent
to their five repetition maximum (8).Whenmuscle failure
ensued, slightly reducing the load several times permitted
the fatigued muscle to complete all 15 repetitions in each
set. A common theme between the present study, our
previous work (8), and other investigations (28, 33) was
completing work to fatigue. This may be an important
consideration when seeking to induce muscle hypertro-
phy to preserve or enhance physical function in older
oncology patients while simultaneously reducing the
absolute load required in patients with disabilities or
limitations.
It has been well documented that to maximize MPS in
older adults, greater protein doses are required. Older
men require;0.4 g of protein/kg/meal (22, 23) to achieve
anabolic effects similar to their younger counterparts
consuming only 0.25 g of protein/kg/meal (24, 25). In the
present study, men on ADT exceeded this threshold
(0.46 g of protein/kg/meal), yet a diminished response
was observed relative to CON for Fed. This suggests that
age-related anabolic resistance to protein intake may be
greater during PCa treatment. Previous research showing
no difference in MPS rates between young men and
women, where testosterone differences are substantial
(30), indirectly supports the notion that androgenic
hormones (i.e., testosterone) are not a primary driver of
meal-induced increases MPS. We propose that these
observations suggest that other factors such as disease
state, ADT length, or habitual physical activity are also
playing a role in determining protein-stimulated increases
in MPS. Surprisingly, ADT length did not influence
resting MPS rates in the present study, which does not
support previous finding where PCa patients on acute
(,6 months) ADT experienced greater muscle atrophy
than did those on chronic ADT (.6 months) (2, 3).
Although the attenuated rise in MPS with Fed raises the
possibility that with ADT greater doses of protein may be
required to maximally stimulate MPS, the MPS response
appears to be independent of length of time since ADT
onset under the current conditions.
Protein supplementation during ADT is limited, and
we are not aware of any data examining MPS, MPB, or
lean mass accretion during testosterone suppression.
Given the attenuated Fed response, future studies should
consider higher protein doses for men undergoing ADT
for PCa and advocating for resistance training to prevent
adverse changes in body composition. Doses may even
need to exceed the 40 g (;0.46 g/kg) used in the present
study to maximize MPS and attenuate MPB to induce
hypertrophy (26).
Indicators of MPB were not measured in the present
study due to limited muscle sample. Therefore, we were
unable to assess changes in MPB during ADT. Hyper-
aminoacidemia and testosterone independently increase
MPS with no change in MPB (34, 35), whereas resistance
exercise increases bothMPS andMBP (36). The net result
is an improvement in fasting net protein balance (34–36).
In hyperaminoacidemia, testosterone reduces MBP and
enhances MPS efficiency (37). It is possible that changes
in inward and outward amino acid transport occurred in
the older men undergoing ADT, and thus with protein
ingestion there may have been a reduction in the amino
acid pool available to stimulate MPS (37), but we are
unable to account for this.
This study had limitations. The sample sizes used were
adequate to determine within-group changes but may be
slightly underpowered to detect between-group differ-
ences for Ex-Fed (1 2 b = 0.556). The original protein
source from the CON (23) was no longer available. The
source used in the ADT group had no substantial dif-
ferences in leucine (4.0 g vs 4.2 g), branched chain amino
acids (3.5 g vs 3.5 g), or essential amino acids (18.4 g vs
18.2 g) and individual amino acid concentration that did
not vary by .1.25% per 40-g serving (Supplemental
Table 1). The design of this study included healthy men
and compared the Fed and Ex-Fed responses during ADT
in a best case scenario. In this initial study, we sought to
examine the effects in the population most affected by
ADT and to see if the response was normal. Although the
effects of resistance exercise only were not included,
current best practice is to consume protein shortly after
exercise (38) and was used in this study.
In summary, the MPS response in older men following
resistance exercise in the Fed state does not appear to be
significantly influenced by systemic concentrations of
testosterone. ADT resulted in a reduced MPS at rest and
with feeding, but structured resistance training with
planned protein ingestion may be advantageous in men
undergoing ADT for PCa by helping alleviate muscle
atrophy. In planning resistance training programs during
ADT, working to fatigue may be a critical factor because
we observed a robust stimulation ofMPS in the Fed state,
and this training style has demonstrated significant
muscle hypertrophy during ADT (8). Future studies
should explore mechanisms underpinning ADT-induced
reductions inMPS at rest and after protein feeding. It will
be important to delineate the amount and timing of
protein consumption that will minimize the side effects of
doi: 10.1210/jc.2016-3383 press.endocrine.org/journal/jcem 1081
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ADT to preserve muscle mass, function, and ultimately
quality of life in men being treated for PCa.
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